Saturday 17 October 2026
Export ZVRA’s income statement to Excel — free account
Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024. In the quarter to June 2026, revenue grew 53.3%, EPS fell 88.7%, free cash flow grew 670.9% and total debt rose 4.07%, each against the same quarter a year earlier.
9.95
0.32
−3.12%
Follow ZVRA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 6 | 3 | 3 | 2 | 6 |
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.54 |
P/S ratio |
— | — | — | 0.00 | 3.36 | 9.05 | 15.38 | 8.82 | 16.34 | 4.65 |
Altman Z-Score |
— | — | — | (37.65) | (32.31) | 25.31 | (2.22) | (2.69) | (3.43) | 0.63 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 25.14 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (89.20) | (78.94) | 22.23 | (5.92) | (8.41) | (10.32) | (0.84) |
Beneish M-Score |
— | — | — | — | (6.75) | (2.32) | 7.85 | (1.17) | (3.86) | 1.46 |
P/Operating CF |
— | — | — | (3.62) | (42.10) | (305.73) | (35.01) | (14.98) | (23.74) | 89.85 |
P/B ratio |
— | — | — | 0.00 | 0.00 | 2.04 | 2.08 | 3.91 | 9.72 | 3.20 |
Price to Tangible BV |
— | — | — | 0.00 | 0.00 | 2.04 | 2.08 | 0.00 | 0.00 | 3.45 |
EV/Sales |
— | — | — | 0.00 | 8.18 | 5.18 | 8.53 | 7.91 | 17.51 | 3.80 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 18.26 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (3.60) | (56.06) | 14.23 | (4.63) | (6.48) | (5.93) | (252.94) |
EV/FCF |
— | — | — | (3.60) | (55.12) | 14.40 | (4.61) | (6.42) | (5.91) | (203.63) |
Quick Ratio |
11.12 | 3.84 | 1.82 | 1.00 | 0.92 | 26.92 | 7.58 | 1.15 | 2.35 | 5.46 |
Current Ratio |
11.20 | 3.99 | 1.98 | 1.28 | 1.11 | 27.20 | 7.72 | 1.18 | 2.53 | 5.68 |
Net Debt/EBITDA |
(0.65) | (1.63) | (1.12) | (4.04) | (21.15) | (13.61) | 1.67 | 0.51 | 0.12 | 39.03 |
Debt/Assets |
108.36% | 178.21% | 306.77% | 741.06% | 610.57% | 1.21% | 11.52% | 24.82% | 33.41% | 21.75% |
Debt/Equity |
(4.92) | (1.63) | (1.23) | (1.05) | (1.03) | 0.01 | 0.18 | 0.69 | 1.50 | 0.40 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.69 | 1.22 | 0.40 | 0.08 | 0.19 | 0.13 | 0.46 |
Operating CF/Net income |
1.80 | 0.76 | 0.96 | 0.97 | 0.15 | (0.17) | 0.70 | 0.73 | 0.66 | (0.02) |
Capex/Depreciation |
(0.36) | (0.10) | (0.01) | (0.01) | (0.01) | (0.25) | (0.10) | (0.29) | 0.00 | (0.01) |
Interest Coverage |
(5.26) | (4.55) | (7.89) | (3.12) | (0.79) | 20.56 | (127.06) | (33.05) | (11.84) | (7.89) |
| 114.63% | 113.86% | 91.01% | 34.78% | 18.12% | (207.22%) | (26.48%) | (67.23%) | (207.84%) | 79.85% | |
| (23.68%) | (63.18%) | (142.59%) | (131.65%) | (117.52%) | (87.27%) | (21.57%) | (32.02%) | (60.21%) | 33.52% | |
ROIC |
(529.65%) | 0.00% | 0.00% | 0.00% | 0.00% | 29.49% | (478.56%) | (84.03%) | (183.25%) | (153.83%) |
Return on Tangible Assets |
(23.70%) | (119.22%) | (419.20%) | (814.14%) | (676.92%) | (56.30%) | (32.81%) | (330.01%) | (201.67%) | 42.12% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 53.02 | 70.84 | 19.47 | 298.11 | 230.97 | 162.45 | 79.73 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 151.22% | 66.55% | 35.47% | 194.89% | 144.95% | 178.28% | 11.97% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 84.24% | 65.84% | 30.37% | 148.00% | 124.96% | 232.37% | 72.90% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.41 | 0.04 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 34.35% | 20.27% | 9.56% | 44.46% | 22.51% | 65.14% | 11.94% |
Graham Net Nets |
— | — | — | (6.95) | (1.55) | 0.42 | 0.34 | (0.10) | (0.14) | 0.19 |
Graham Number |
— | — | — | 112.82 | 34.81 | 0.00 | 0.00 | 0.00 | 0.00 | 9.28 |
Earnings Yield |
— | — | — | (232.34%) | (28.82%) | (32.75%) | (17.05%) | (18.38%) | (26.86%) | 15.29% |
Free Cash Flow Yield |
— | — | — | (211.62%) | (4.42%) | 3.98% | (12.04%) | (13.97%) | (18.14%) | (0.40%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 6.93 | 3.34 | 0.96 | 0.29 | 0.77 | 0.51 | 1.92 |
Operating CF per Share |
(32.63) | (36.14) | (48.37) | (12.81) | (0.49) | 0.35 | (0.54) | (0.95) | (1.51) | (0.03) |
Capex per Share |
(0.70) | (0.20) | (0.02) | (0.01) | (0.01) | 0.00 | 0.00 | (0.01) | 0.00 | (0.01) |
Free Cash Flow per Share |
(33.34) | (36.34) | (48.39) | (12.82) | (0.50) | 0.35 | (0.55) | (0.95) | (1.51) | (0.04) |
Cash per Share |
75.49 | 46.11 | 19.34 | 1.92 | 1.09 | 3.77 | 2.40 | 1.91 | 1.50 | 3.45 |
Shareholders Equity per Share |
(20.49) | (62.80) | (59.40) | (40.18) | (16.68) | 4.27 | 2.18 | 1.75 | 0.86 | 2.80 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(20.49) | (62.80) | (59.40) | (40.18) | (16.68) | 4.27 | 2.18 | 1.75 | 0.86 | 2.80 |
Free Cash Flow |
(30.41) | (33.28) | (54.22) | (23.76) | (1.97) | 10.34 | (18.81) | (33.83) | (69.66) | (1.98) |
Working Capital |
67.72 | 34.39 | 11.72 | 1.54 | 0.85 | 110.83 | 80.81 | 13.22 | 51.96 | 183.73 |
Capital Expenditures |
(0.64) | (0.18) | (0.02) | (0.03) | (0.03) | (0.10) | (0.09) | (0.30) | — | (0.39) |
Net Current Asset Value |
(29.23) | (64.08) | (69.59) | (77.99) | (69.24) | 109.23 | 52.61 | (23.52) | (52.43) | 92.93 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 19.22 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 33.54 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.91 | 0.95 | 1.11 | 1.33 | 2.48 | 0.46 | 1.19 | 1.37 | 15.45 | 121.96 |
Cash ROIC |
(21.40%) | (42.56%) | (145.96%) | (341.32%) | (31.06%) | 4.29% | (10.98%) | (19.63%) | (41.30%) | (0.49%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 12.81 | 5.98 | 13.95 | 2.07 | 2.14 | 1.69 | 6.31 |
Accounts Payable Turnover |
0.03 | 0.05 | 0.04 | 0.44 | 0.23 | 0.43 | 0.05 | 0.13 | 0.28 | 0.89 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.89 |
Average Days of Payables |
13,440.34 | 8,554.69 | 9,397.62 | 608.66 | 1,859.12 | 538.55 | 10,142.73 | 4,770.87 | 1,252.72 | 256.84 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 96.95 | 38.53 |
Average Receivables |
3.54 | 3.50 | 1.07 | 1.00 | 2.22 | 2.05 | 4.91 | 12.84 | 13.94 | 16.88 |
Average Payables |
5.68 | 7.16 | 8.11 | 6.63 | 5.78 | 4.84 | 4.60 | 17.29 | 26.93 | 18.53 |
Average Inventory |
— | — | — | — | — | — | — | — | — | 1.86 |
Average Assets |
69.74 | 68.67 | 39.60 | 18.63 | 10.86 | 72.08 | 124.14 | 143.83 | 175.23 | 231.43 |
Average Common Equity |
(14.41) | (38.11) | (62.04) | (70.51) | (70.43) | 30.35 | 101.12 | 68.49 | 50.77 | 97.16 |
Columns are period end dates